SVRD方案治疗伴髓外病变新诊断多发性骨髓瘤的2期试验
这项多中心、开放标签、单臂2期试验评估了塞利尼索联合硼替佐米、来那度胺和地塞米松(SVRD)方案在伴髓外病变(EMD)的新诊断多发性骨髓瘤(NDMM)患者中的疗效与安全性。29例可评估患者中,总缓解率(ORR)达89.7%,影像学EMD消退率89.7%,12个月无进展生存率和总生存率分别为87.9%和96.3%,≥3级不良事件发生率37.3%,未发生治疗相关死亡。
要点
- SVRD在伴EMD的NDMM中ORR达89.7%,严格完全缓解率58.6%。
- 影像学EMD完全消退率79.3%,12个月PFS率87.9%,OS率96.3%。
- ≥3级不良事件发生率37.3%,以血小板减少(24.1%)最常见,无治疗相关死亡。
核心结论
- SVRD方案在伴EMD的新诊断多发性骨髓瘤中产生深度血液学缓解和高EMD清除率,毒性可控。
- 研究结果支持SVRD作为EMD阳性NDMM的合理一线选择,并值得开展随机研究以确认持久性。
研究设计与样本
- 多中心、开放标签、单臂、2期、研究者发起的临床试验(NCT05900882)。
- 诱导治疗为4个28天周期的SVRD方案,后续按方案进行巩固/维持治疗,并可选自体造血干细胞移植(ASCT)。
- 主要终点为诱导期间根据国际骨髓瘤工作组标准的最佳总缓解率(ORR),无基线后评估者归为无缓解。
主要发现
- mITT人群中ORR为89.7%(严格完全缓解58.6%,完全缓解3.4%,非常好的部分缓解10.3%,部分缓解17.2%)。
- 影像学记录到89.7%的患者EMD消退(完全消退79.3%,部分消退10.3%)。
- 12个月无进展生存率和总生存率分别为87.9%和96.3%(中位数未达到;中位随访18个月)。
- 31.0%的患者存在高危细胞遗传学,27.6%符合超高危(双打击)标准。
- ≥3级治疗中出现的不良事件发生率为37.3%,最常见为血小板减少(24.1%)、中性粒细胞减少(6.9%)和肺炎(10.3%);无治疗相关死亡。
关键数值与推荐
- 主要终点ORR定义为诱导期间最佳总缓解率,按国际骨髓瘤工作组标准评估,无基线后评估者归为无缓解。
- mITT人群ORR为89.7%,严格完全缓解率58.6%。
- 影像学EMD消退率89.7%,其中完全消退79.3%。
- 12个月PFS率87.9%,OS率96.3%。
- ≥3级TEAE发生率37.3%,最常见为血小板减少24.1%。
临床怎么用
- SVRD可作为伴EMD的新诊断多发性骨髓瘤患者的一线治疗选择,能实现深度缓解和高EMD清除。
- 该方案毒性可控,支持后续进行ASCT(51.7%受试者接受移植)。
- 需随机研究确认持久性,并与当代四药联合方案和细胞治疗进行基准比较。
局限性
- 单臂设计,无对照组,样本量较小(29例可评估)。
- 随访时间较短(中位18个月),PFS和OS中位数未达到。
- 研究为开放标签,可能存在评估偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extramedullary disease (EMD) at diagnosis confers a poor prognosis in newly diagnosed multiple myeloma (NDMM). This multicenter, open-label, single-arm, phase 2, investigator-initiated trial evaluated selinexor combined with bortezomib, lenalidomide, and dexamethasone (SVRD) in NDMM with EMD. Between 17 October 2022 and 27 November 2025, 30 patients were enrolled; 29 treated patients formed the modified intention-to-treat (mITT) and safety populations (median age, 60 years). Induction comprised four 28-day SVRD cycles with protocol-specified consolidation/maintenance and optional autologous stem cell transplantation (ASCT). The primary end point was best overall response rate (ORR) during induction according to International Myeloma Working Group criteria. Patients without a postbaseline assessment were imputed as nonresponders. In the mITT cohort, the ORR was 89.7% (stringent complete response [CR], 58.6%; CR, 3.4%; very good partial response, 10.3%; partial response, 17.2%). Imaging documented EMD regression in 89.7% of patients (complete resolution, 79.3%; partial resolution, 10.3%). The 12-month progression-free survival and overall survival rates were 87.9% and 96.3%, respectively (medians not reached; median follow-up, 18 months). High-risk cytogenetics were present in 31.0% of patients, and 27.6% met the ultra-high-risk (double-hit) criteria. Grade ≥3 treatment-emergent adverse events occurred in 37.3% of patients, most commonly thrombocytopenia (24.1%), neutropenia (6.9%), and pneumonia (10.3%); no treatment-related deaths occurred. SVRD produced deep hematologic responses and high EMD clearance with manageable toxicity, thereby enabling ASCT in 51.7% of participants. These findings support SVRD as a rational frontline option for EMD-positive NDMM and justify randomized studies to confirm durability and to benchmark it against contemporary quadruplets and cellular therapies. This trial was registered at www.ClinicalTrials.gov as NCT05900882.
引用
- Jin Y, Cheng X, Zhang X, et al. Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial. Blood Adv. 2026. PMID: 41564431. doi:10.1182/bloodadvances.2025018945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。